Clinical trials: Relapsed and Refractory Multiple Myeloma (RRMM)
Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Background: Multiple Myeloma remains an incurable hematologic malignancy, and outcomes for relapsed/refractory multiple myeloma (RRMM) remain unsatisfactory despite advances in therapy.
- Trial name
- NCT07497165
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanxi Bethune Hospital
Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- ALUMMINATE (NCT06232707)
- Testing
- Alnuctamab, Pomalidomide, Daratumumab
- Where
- 170 sites in United States, Argentina and 25 more
- Sponsor
- Celgene
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November…
- Trial name
- NCT05297240
- Testing
- Belantamab mafodotin
- Where
- 62 sites in Spain
- Volunteers
- 170 people
- Sponsor
- PETHEMA Foundation
Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Despite advances in multiple myeloma (MM) therapy, patients continue to suffer from frequent relapses and treatment-resistant disease.
- Trial name
- Mezi-KD (NCT07348393)
- Testing
- Administration of a combination of treatments
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple…
- Trial name
- NCT02045017
- Testing
- Pomalidomide and Dexamethasone
- Where
- 22 sites in Austria, France and 6 more
- Volunteers
- 81 people
- Sponsor
- Celgene
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus…
- Trial name
- BOSTON (NCT03110562)
- Testing
- Selinexor, Bortezomib, Dexamethasone
- Where
- 157 sites in United States, Australia and 19 more
- Volunteers
- 402 people
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed or Refractory Multiple Myeloma (RRMM)
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07715630
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed and Refractory Multiple Myeloma (RRMM)
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.
- Trial name
- NCT06479954
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies.
- Trial name
- NCT04941937
- Testing
- Selinexor, Thalidomide, Lenalidomide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Juan Du
Plasma Cell Myeloma Refractory
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy.
- Trial name
- NCT04643002
- Testing
- Isatuximab, Dexamethasone, Pomalidomide
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 258 people
- Sponsor
- Sanofi
Plasma Cell Myeloma
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Primary Objectives: To evaluate the safety and tolerability of the combination of isatuximab (also known as SAR650984) and cemiplimab (also known as REGN2810) in patients with relapse/refractory multiple myeloma.
- Trial name
- NCT03194867
- Testing
- Isatuximab SAR650984, Cemiplimab REGN2810
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Relapsed/Refractory Multiple Myeloma
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
- Trial name
- ProxiMMity-1 (NCT04998747)
- Testing
- AMG 701
- Sponsor
- Amgen
Multiple Myeloma
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38…
- Trial name
- NCT05217082
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT04776018
- Testing
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Where
- 13 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Takeda
Multiple Myeloma in Relapse
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
This is an open-label clinical study to evaluate the efficacy and safety of a multicenter, open-label clinical study of a base-reduced-dose pomalidomide, cyclophosphamide combined with dexamethasone (PCd) regimen for the…
- Trial name
- NCT06255847
- Testing
- Pomalidomide, cyclophosphamide combined with dexametha
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanxi Bethune Hospital
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center